-
Published 1/1/2026
Alexander KM, Davis MK, Akinboboye O, Berk J, Bhatt K, Cappelli F, Cuddy SAM, Fontana M, Garcia-Pavia P, Gillmore JD, Griffin JM, Grodin JL, Judge DP, Khouri MG, Lam K, Masri A, Maurer MS, Obici L, Ruberg FL, Sarswat N, Shah K, Soman P, Stern L, Wright R, Xiong K, Cao X, Lystig T, Tamby JF, Castaño A, Katz L, Sinha U, Fox JC, Solomon SD, Grogan M. Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension. JAMA Cardiol. 2026 Jan 01; 11(1):57-67. PMID: 41205147.
-
Published 10/28/2025
Wixner J, Conceição I, Berk JL, Adams D, Polydefkis MJ, Attarian S, Gillmore JD, Dyck PJB, Chen J, Kwoh TJ, Nåtman J, Zhou W, Cruz MW. Neuropathy impairment and nutritional status with eplontersen in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2026 Mar; 33(1):85-89. PMID: 41147681.
-
Published 8/12/2025
Maurer MS, Berk JL, Damy T, Sheikh FH, González-Costello J, Morbach C, Delgado D, Bondue A, Azevedo O, Poulsen SH, Jankowska EA, Yang L, Bender S, Eraly SA, Jay PY, Vest J, Fontana M. Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B. J Am Coll Cardiol. 2025 Aug 12; 86(6):459-475. PMID: 40769675.
-
Published 6/23/2025
Berk JL, Lairez O, Schwartzmann P, Bender S, White MT, Jay PY, Danese D, Witteles R. Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis: Post Hoc Analysis of APOLLO-B. JACC Adv. 2025 Aug; 4(8):101876. PMID: 40555140.
-
Published 3/31/2025
Fontana M, Berk JL, Drachman B, Garcia-Pavia P, Hanna M, Lairez O, Witteles R. Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2025 Aug; 18(8):e012112. PMID: 40160093.